Handelsavisen
prelaunch
Companies Healthcare NTRB.O
NT
NTRB.O NASDAQ Diversified Medical Equipment & Supplies

Nutriband Inc

$2,81
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
34,2M USD
P/E
EV / Rev
Div yield
Op margin
-408,4 %
ROE
-123,2 %
Net margin
-404,1 %
Debt / equity
0,02
Beta
52w range
Volume
157
Day range
$3,21–$3,50
Prev close
$3,40
Open
$3,39
Next earnings
2026-08-28
Ex-dividend
TR 1Y
About

Nutriband Inc is a medical equipment and supplies company that designs, develops, and markets wearable health monitoring devices, primarily focused on sleep apnea treatment and other respiratory conditions.

Business. Nutriband Inc (NTRB.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Nutriband is headquartered in the United States and is primarily listed on the NASDAQ stock exchange.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target15,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
15,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
-123,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NTRB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NTRB.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-08-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nutriband Inc (NTRB.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Nutriband is headquartered in the United States and is primarily listed on the NASDAQ stock exchange.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Nutriband Inc operates with a capital structure that is highly liquid, as evidenced by $4.57 million in cash and equivalents, which significantly exceeds its total liabilities of $0.87 million. The company's liquidity position is further reinforced by a debt-to-equity ratio of 0.02, indicating minimal leverage. However, the company reported negative operating cash flow of $5.13 million, which raises concerns about its ability to sustain operations without external financing.

    Profitability metrics are deeply negative, with a net loss of $8.23 million and an operating loss of $8.32 million. The return on equity is -1.23, which is far below the typical performance of companies in the medical equipment industry. The company's EV/EBITDA ratio is negative at -4.60, reflecting the unprofitable nature of its operations. These figures suggest that Nutriband is not currently generating returns that meet industry expectations.

    The company's revenue is concentrated in a single business segment, as no segmental breakdown is disclosed. Geographically, Nutriband's exposure is not explicitly detailed in the available data, but the company's operations are likely centered in the United States given the lack of international revenue disclosures. This lack of diversification increases the company's vulnerability to regional economic or regulatory shifts.

    Nutriband's growth trajectory is uncertain, as the company reported a revenue of $2.04 million in the latest period. Analysts have assigned a mean price target of $15.00, which is significantly higher than the current market price of $3.51. However, the company's negative operating cash flow and net loss suggest that achieving this target will require substantial operational improvements or external capital infusions.

    The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative operating cash flow and net loss raise concerns about the company's ability to maintain its current capital structure without issuing additional shares. The dilution potential is currently low, but the company's financial performance could necessitate equity financing in the near term.

    Recent events include the publication of the latest financial data, which shows a significant decline in profitability. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational challenges. The lack of detailed disclosures limits the ability to assess the company's long-term viability.

    Key takeaways
    • Nutriband Inc is a medical equipment company with a highly liquid balance sheet but significant operational losses.
    • The company's negative operating cash flow and net loss indicate a need for external financing or operational improvements.
    • Analysts have assigned a high price target, but the company's current financial performance does not support this optimism.
    • The company's lack of segmental and geographic diversification increases its vulnerability to regional risks.
    • Nutriband's risk profile is currently low, but its financial performance could necessitate equity financing in the near term.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2,81
    Market cap
    $42.7M
    Enterprise value
    $38.3M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    $4.4M
    Current ratio
    Debt / equity
    0.0
    ROA
    ROE
    -1.2%
    Cash conversion
    62.0%
    CapEx / revenue
    -0.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setNTRB 0,0% · rank #76 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs NTRB · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +135,7 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +132,9 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +136,7 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +130,2 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +126,2 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    +107,8 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +154,0 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$15,00 · Median $15,00
    Low $15,00High $15,00

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$15,00
    Mean$15,00
    Median$15,00
    High$15,00
    Spot$2,81
    +433.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-408,4 %Bottom quartile
    Net Margin-404,1 %Bottom quartile
    ROE-123,2 %Bottom quartile
    Capex / Rev-0,3 %Above median
    D/E0,02Above median
    Cash Conv0,62Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Nutriband Inc Market data — financials · 2026-05-28
    • Nutriband Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Insider activity

    — missing data

    Short positioning

    156.9Kshares short+2.5% vs prior
    11.36days to cover
    36.5%short of daily vol
    221fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NTRB.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Operating income (YoY) (2026-01-31 vs 2025-01-31): 19.1%Derived (calculated)
    • Net income (YoY) (2026-01-31 vs 2025-01-31): 21.5%Derived (calculated)
    • Gross profit (YoY) (2026-01-31 vs 2025-01-31): -23.8%Derived (calculated)
    • Capex (YoY) (2026-01-31 vs 2025-01-31): -94.2%Derived (calculated)
    • EPS (diluted) (YoY) (2026-01-31 vs 2025-01-31): -160.6%Derived (calculated)
    • Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -16.6%Derived (calculated)
    • Total assets (YoY) (2026-01-31 vs 2025-01-31): 1.0%Derived (calculated)
    • Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 3.9%Derived (calculated)
    • Revenue (YoY) (2026-01-31 vs 2025-01-31): -4.8%Derived (calculated)
    • R&D expense (YoY) (2026-01-31 vs 2025-01-31): -39.4%Derived (calculated)
    • Cost of revenue (YoY) (2026-01-31 vs 2025-01-31): 5.3%Derived (calculated)
    • EPS (basic) (YoY) (2026-01-31 vs 2025-01-31): -160.6%Derived (calculated)
    • Cash & equivalents (YoY) (2026-01-31 vs 2025-01-31): 6.1%Derived (calculated)
    • Net margin (FY 2026-01-31): -404.1%Derived (calculated)
    • Gross margin (FY 2026-01-31): 27.8%Derived (calculated)
    • Return on equity (FY 2026-01-31): -123.2%Derived (calculated)
    • Return on assets (FY 2026-01-31): -109.0%Derived (calculated)
    • Current ratio (FY 2026-01-31): 6.36xDerived (calculated)
    • Debt-to-equity (FY 2026-01-31): 0.13xDerived (calculated)
    • Operating cash flow (YoY) (2026-01-31 vs 2025-01-31): -11.0%Derived (calculated)
    • Capex (annual): USD 5.32KSEC XBRL filing
    • Operating income (annual): USD -8.32MSEC XBRL filing
    • Revenue (annual): USD 2.04MSEC XBRL filing
    • Cash & equivalents (annual): USD 4.57MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-06-11FILINGQUARTERLY REPORT →
    2026-04-29FILINGANNUAL REPORT →
    2026-04-07FILINGCURRENT REPORT →
    2026-02-13FILINGCURRENT REPORT →
    2026-02-03FILINGCURRENT REPORT →
    2025-12-30FILINGCURRENT REPORT →
    2025-12-19FILINGPROXY STATEMENT →
    2025-12-11FILINGQUARTERLY REPORT →
    2025-10-28FILINGCURRENT REPORT →
    2025-09-09FILINGQUARTERLY REPORT →
    2025-01-29 00:00 UTCINSIDER2 insider transactions — 2025-01 2 derivative
    2024-06-06 00:00 UTCINSIDER2 insider transactions — 2024-06 2 derivative
    2024-03-20 00:00 UTCINSIDER5 insider transactions — 2024-03 5 derivative
    2023-10-27 00:00 UTCINSIDER2 insider transactions — 2023-10 · net buy $116k 1 derivative
    2023-03-06 00:00 UTCINSIDER1 insider transaction — 2023-03
    2022-12-09 00:00 UTCINSIDER1 insider transaction — 2022-12 1 derivative
    2022-08-16 00:00 UTCINSIDER1 insider transaction — 2022-08 1 derivative
    2022-06-15 00:00 UTCINSIDER1 insider transaction — 2022-06
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage